Literature DB >> 8548340

Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein.

J Friborg1, A Ladha, H Göttlinger, W A Haseltine, E A Cohen.   

Abstract

The human immunodeficiency virus type 1 (HIV-1)-encoded vpu product is a small class 1 integral membrane protein that is phosphorylated by the ubiquitous casein kinase II (CKII) in HIV-1-infected cells. The Vpu protein facilitates the release of budding virions from the surface of infected cells and delays the rate of syncytium formation. In this study, we investigated the role of phosphorylation in the biological activity of Vpu. Our results show that phosphorylation of Vpu occurs on serine residues at positions 52 and 56 located in a highly conserved dodecapeptide sequence. Mutation of either Ser 56, or both Ser 52 and Ser 56 impaired the ability of Vpu to delay the rate of syncytium formation while retaining virion release activity at levels comparable to vpu+ proviruses. Flow cytometry analysis indicates that the relative amounts of envelope glycoprotein gp120 expressed at the surface of cells transfected with these vpu mutant proviruses was two- to threefold greater than that observed on cells transfected with a vpu+ provirus. This increased expression of gp120 at the cell surface may explain the more rapid onset of syncytium formation observed in cell transfected with vpu mutant proviruses. These results suggest that Vpu-facilitated virion release and delayed cytopathic effect are the consequence of two distinct functional activities of the protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548340

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  32 in total

1.  vpu transmembrane peptide structure obtained by site-specific fourier transform infrared dichroism and global molecular dynamics searching.

Authors:  A Kukol; I T Arkin
Journal:  Biophys J       Date:  1999-09       Impact factor: 4.033

2.  Structural implications of mutations assessed by molecular dynamics: Vpu1-32 from HIV-1.

Authors:  J Krüger; Wolfgang B Fischer
Journal:  Eur Biophys J       Date:  2009-06-09       Impact factor: 1.733

3.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

4.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

5.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

6.  Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Julie Binette; Johanne Mercier; Antoine Chiasson; Eric A Cohen
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

Review 7.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

Review 8.  The great escape: viral strategies to counter BST-2/tetherin.

Authors:  Janet L Douglas; Jean K Gustin; Kasinath Viswanathan; Mandana Mansouri; Ashlee V Moses; Klaus Früh
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

9.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.

Authors:  Amy J Andrew; Eri Miyagi; Sandra Kao; Klaus Strebel
Journal:  Retrovirology       Date:  2009-09-08       Impact factor: 4.602

10.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Carina Banning; Peter Wimmer; Herwig Koppensteiner; Alicja Iwanski; Anke Specht; Daniel Sauter; Thomas Dobner; Frank Kirchhoff
Journal:  Retrovirology       Date:  2010-01-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.